The American pharmaceutical giant Eli-Lilly has consistently denied any link between Zyprexa, its antipsychotic drug, and diabetes, was concerned about the side-effects of the drug as early as 1998, according to leaked court documents.

Those leaked court documents suggest that the company was aware of the risks of weight gain, hyperglycemia and diabetes associated with the drug but presented them as common problems across the whole class of schizophrenia drugs.